Paliperidone Extended-Release Tablets bulk supplier for pharma manufacturers

Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, 9 mg Suppliers & Bulk Manufacturers

Available Forms: Extended-Release Tablets

Available Strengths: 1.5 mg, 3 mg, 6 mg, 9 mg

Reference Brands: Invega®(US & EU)

Paliperidone is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors, helping to reduce symptoms of schizophrenia and improve mood stability. The extended-release (ER) tablets use an OROS delivery system to provide steady plasma levels over 24 hours, minimizing fluctuations and side effects. They are used for the treatment of schizophrenia and schizoaffective disorder in adults.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Paliperidone extended-release tablets (brand name: Invega) are FDA-approved in the United States for the treatment of schizophrenia and schizoaffective disorder in adults. In the European Union, they are authorized under the centralized procedure for schizophrenia. Regulatory requirements include GMP-compliant manufacturing, osmotic-controlled release oral delivery system (OROS) data, and comprehensive clinical efficacy and safety studies. The product labeling in the U.S. includes a boxed warning for increased mortality in elderly patients with dementia-related psychosis. EU authorization also mandates Risk Management Plans (RMPs) and post-marketing safety monitoring. To explore dossier-ready Paliperidone ER tablets, visit Pharmatradz.com.

Paliperidone Extended-Release Tablets — third party manufacturing & bulk supply

Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, 9 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Paliperidone Extended-Release Tablets is supplied as Extended-Release Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Paliperidone Extended-Release Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Paliperidone Extended-Release Tablets →

Back to Listing

Frequently Asked Questions

Paliperidone Extended-Release Tablets is listed as Extended-Release Tablets in 1.5 mg, 3 mg, 6 mg, 9 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Paliperidone Extended-Release Tablets is referenced against Invega®(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.